A pharmaceutical company successfully defended a securities fraud shareholder class action challenging the company’s valuation of auction rate securities in a case involving a single-day, $600 million market drop. Our firm represented the pharmaceutical company and obtained court approval of a classwide settlement of less than $2 million (including attorneys’ fees and notice costs). We also achieved dismissal of a related shareholder derivative suit.
Pharmaceutical Company Successfully Defends Securities Fraud Shareholder Class Action
Lead Contacts
